By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MedImmune 

One MedImmune Way

Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-398-0000 Fax: 301-398-9000


SEARCH JOBS

MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.

With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.

Key Statistics


Email:
Ownership: Public

Web Site: MedImmune
Employees: 3,000
Symbol: AZN
 



Industry
Biotechnology






Company News
Advaxis, Inc. And MedImmune (AZN) Commence Enrollment In Phase I/II Study Of Axalimogene Filolisbac (ADXS-HPV) In Combination With Durvalumab (MEDI4736) For The Treatment Of HPV-Associated Cancers 8/20/2015 7:59:57 AM
Cellular Biomedicine Group (CBMG) Appoints Former MedImmune (AZN)/AstraZeneca PLC (AZN) Senior Director, Yihong Yao, Ph.D., B.S., As Chief Scientific Officer 8/11/2015 7:59:56 AM
AstraZeneca PLC (AZN)'s MedImmune (AZN) and Mirati Therapeutics  (MRTX) Partner Up on Immuno-Oncology Combination In Lung Cancer 8/5/2015 5:49:40 AM
Dr. David Berman Joins MedImmune (AZN) As Head Of Oncology 7/21/2015 2:44:13 PM
MedImmune (AZN) Appoints Diabetes Researcher Dr. Christopher Rhodes As Head Of Cardiovascular And Metabolic Disease Research 7/14/2015 2:30:54 PM
BIO2015 EXCLUSIVE: Brazil and Biotech Go Hand in Glove, MedImmune (AZN) Exec Tells BioSpace (DHX) 6/19/2015 9:24:21 AM
BIO2015 EXCLUSIVE: MedImmune (AZN) Exec Says Key to Ending “Superbugs” Is Personalized Medicine 6/17/2015 2:58:29 PM
ASCO15: AstraZeneca PLC (AZN) And MedImmune (AZN) Present Positive Immuno-Oncology Combination Data At ASCO 2015 6/1/2015 8:46:32 AM
MedImmune (AZN) And Juno Therapeutics (JUNO) Announce Immuno-Oncology Clinical Trial Collaboration 4/23/2015 6:32:17 AM
Immunocore Limited And MedImmune (AZN) Announce New Collaboration To Conduct Immuno-Oncology Combination Trails In Melanoma 4/16/2015 6:33:40 AM
12345678910...
//-->